Moleculin Biotech is trading 6.26% up in pre-market at $0.73 after announcing its August 27, 2026 participation in Virtual Investor’s “Why Now” on-demand conference.
- Presentation highlighted positive interim MIRACLE trial data, including complete remission rates three times higher than control.
- Planned 90-patient enrollment milestone in September 2026; unblinded efficacy readout expected in December 2026.
- No separate earnings or regulatory announcement was identified for August 28, 2026.